Search results for "From ACP Internist"
ADA updates diabetes standards of care for 2023
The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.
https://diabetes.acponline.org/archives/2023/01/13/5.htm
13 Jan 2023
Getting to know GLP-1 receptor agonists
The latest Pearls from I.M. Peers offers advice on prescribing glucagon-like peptide-1 (GLP-1) receptor agonists for patients with diabetes.
https://diabetes.acponline.org/archives/2023/03/10/8.htm
10 Mar 2023
Overweight, obesity poorly managed in type 1 diabetes
While U.S. adults with type 1 diabetes have rates of overweight and obesity virtually identical to those in the general adult population, only about 50% received lifestyle recommendations for weight management from clinicians or tried lifestyle modifications.
https://diabetes.acponline.org/archives/2023/03/10/9.htm
10 Mar 2023
New recommendations advise on adding SGLT-2 inhibitors and GLP-1 receptor agonists
A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, in addition to offering weaker support for starting glucagon-like peptide-1 (GLP-1) receptor agonists in this same patient population.
https://diabetes.acponline.org/archives/2021/06/11/7.htm
11 Jun 2021
GLP-1 receptor agonists associated with thyroid cancer
Patients taking a glucagon-like peptide-1 (GLP-1) receptor agonist had about one and a half times the risk of developing thyroid cancer compared to similar controls, according to an observational French study.
https://diabetes.acponline.org/archives/2022/12/09/6.htm
9 Dec 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/12/09/7.htm
9 Dec 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
ADA, EASD update guidance on managing hyperglycemia
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
https://diabetes.acponline.org/archives/2022/10/14/7.htm
14 Oct 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
Treatment pathways compared for diabetic peripheral neuropathy
Amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective for controlling pain, a recent study found.
https://diabetes.acponline.org/archives/2022/09/16/7.htm
16 Sep 2022